SABS News and Press, SAB Biotherapeutics Inc. From 04/19/23

2023-04-19 12:49:23 ET Gainers: SAI.TECH Global Corporation ( SAI ) +48% . Bed Bath & Beyond ( BBBY ) +40% . VYNE Therapeutics ( VYNE ) +34% . Boqii Holding Limited ( BQ ) +30% . CXApp ( CXAI ) +19% . Western Alliance Ban...

2023-04-19 10:05:08 ET Gainers: Vyne Therapeutics ( VYNE ) +32% . Ensysce Biosciences ( ENSC ) +23% . Legend Biotech ( LEGN ) +20% . Tempest Therapeutics ( TPST ) +16% . Evoke Pharma ( EVOK ) +14% . Losers: Allarity T...

2023-04-19 08:21:42 ET Allarity Therapeutics ( ALLR ) -33% . Femasys ( FEMY ) -25% anounces $3.9 million registered direct offering. Oblong ( OBLG ) -21% . Gamida Cell ( GMDA ) -16% on public offering . United Insurance Holdings ( ...

2023-04-18 08:47:12 ET SAB Biotherapeutics ( NASDAQ: SABS ) is up ~12% in premarket trading Tuesday after the US FDA granted Breakthrough Therapy designation for its influenza immunotherapy candidate SAB-176. The drug is for post-exposure prophylaxis for Type ...

SAB-176 has now received both Breakthrough and Fast Track designations from FDA – signifying its potential to fundamentally improve influenza treatment and prophylaxis Influenza therapeutic now eligible for intensive guidance from FDA for an efficient development program ...

2023-04-13 09:44:17 ET SAB Biotherapeutics' ( NASDAQ: SABS ) stock rose ~87% on Thursday after the company said the U.S Food and Drug Administration (FDA) granted fast track designation to influenza therapy SAB-176. The company noted SAB-176 is a first fully-human bro...

FDA greenlights advancement of SAB-176 Phase 2b trial and manufacturing approach to address influenza strain change SAB-176 is the first fully-human broadly neutralizing immunoglobulin antibody therapeutic intended to prevent or reduce severe outcomes of Type A and Type B influenza infe...

SIOUX FALLS, S.D., April 04, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS ), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human immunoglobulin (hIgG) antibodies, also known as f...

SIOUX FALLS, S.D., March 31, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics ( Nasdaq: SABS ), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human immunoglobulin (hIgG) antibodies, also known as ...

SIOUX FALLS, S.D., Jan. 19, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS ), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, high-avidity, fully-human polyclonal antibodies without the need for ...